直接口服抗凝药治疗期间发生缺血性卒中患者的替代抗凝策略与结局的关联
该研究基于香港2015年1月1日至2020年12月31日的人群回顾性队列,纳入2337例直接口服抗凝药(DOAC)治疗期间首次发生缺血性卒中的非瓣膜性房颤患者。与维持原DOAC方案相比,换用华法林(aHR 1.96,95%CI 1.27-3.02,p=0.002)和换用另一种DOAC(aHR 1.62,95%CI 1.25-2.11,p<0.001)与复发性缺血性卒中风险增加相关。在维持原DOAC组中,联用抗血小板药与复发性缺血性卒中风险降低无关。
要点
- DOAC期间发生缺血性卒中的非瓣膜性房颤患者,换用华法林较维持原DOAC的复发性缺血性卒中风险增加(aHR 1.96,95%CI 1.27-3.02,p=0.002)。
- 换用另一种DOAC同样与复发性缺血性卒中风险增加相关(aHR 1.62,95%CI 1.25-2.11,p<0.001),需进一步研究。
- 在维持原DOAC组中,联用抗血小板药未降低复发性缺血性卒中风险;糖尿病、CYP/P-gp调节剂和大动脉粥样硬化性疾病是预测因素。
核心结论
- 在DOAC治疗期间发生缺血性卒中的非瓣膜性房颤患者中,换用华法林与复发性缺血性卒中风险增加相关,作者呼吁慎用该做法。
- 换用另一种DOAC与缺血性卒中风险增加相关,需要进一步研究。
- 联用抗血小板药似乎未降低缺血性卒中复发。
- 糖尿病、CYP/P-gp调节剂使用和大动脉粥样硬化性疾病是复发性缺血性卒中的预测因素,作者建议进一步研究严格血糖控制、DOAC水平监测和颈动脉及颅内动脉粥样硬化常规筛查是否可减少复发。
研究设计与样本
- 该研究为基于人群的倾向评分加权回顾性队列研究,比较DOAC期间发生首次缺血性卒中的非瓣膜性房颤患者不同抗血栓策略的临床结局。
- 研究纳入2015年1月1日至2020年12月31日期间香港45,946例以DOAC预防卒中的房颤患者中2,908例发生缺血性卒中者,最终分析纳入2,337例非瓣膜性房颤患者。
- 主要结局为复发性缺血性卒中,次要结局为颅内出血、急性冠脉综合征和死亡。
- 采用竞争风险回归分析比较临床终点,并用未加权多变量logistic回归模型确定复发性缺血性卒中的预测因素。
主要发现
- 与维持原DOAC方案相比,换用华法林与复发性缺血性卒中风险增加相关(aHR 1.96,95%CI 1.27-3.02,p=0.002)。
- 与维持原DOAC方案相比,换用另一种DOAC与复发性缺血性卒中风险增加相关(aHR 1.62,95%CI 1.25-2.11,p<0.001)。
- 在维持原DOAC组中,联用抗血小板药与复发性缺血性卒中风险降低无关。
- 糖尿病、同时使用细胞色素P450/P-糖蛋白(CYP/P-gp)调节剂和大动脉粥样硬化性疾病是复发性缺血性卒中的预测因素。
关键数值与推荐
- 该研究提供II级证据:在DOAC治疗期间发生缺血性卒中的非瓣膜性房颤患者中,继续原DOAC治疗在预防复发性缺血性卒中方面优于换用另一种DOAC或华法林。
- 换用华法林与复发性缺血性卒中风险增加相关(aHR 1.96,95%CI 1.27-3.02,p=0.002)。
- 换用另一种DOAC与复发性缺血性卒中风险增加相关(aHR 1.62,95%CI 1.25-2.11,p<0.001)。
- 在维持原DOAC组中,联用抗血小板药与复发性缺血性卒中风险降低无关。
临床怎么用
- 作者认为,换用华法林与复发性缺血性卒中风险增加相关,呼吁慎用该做法。
- 作者认为,换用另一种DOAC与缺血性卒中风险增加相关,需要进一步研究。
- 作者认为,联用抗血小板药似乎未降低缺血性卒中复发。
- 作者建议进一步研究严格血糖控制、DOAC水平监测和颈动脉及颅内动脉粥样硬化常规筛查是否可减少这些患者的缺血性卒中复发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Ischemic stroke despite a direct oral anticoagulant (DOAC) is increasingly common and portends a high risk of subsequent ischemic stroke. The efficacy and safety of antithrombotic regimens after the condition are unclear. We aimed to compare the outcomes of patients with ischemic stroke despite DOACs with and without an alternative antithrombotic regimen and determine the risk factors of recurrent ischemic stroke while on anticoagulation. METHODS: In a population-based, propensity score-weighted, retrospective cohort study, we compared the clinical outcomes of DOAC-to-warfarin switch, DOAC-to-DOAC switch (DOACswitch), or addition of antiplatelet agents, with those of unchanged DOAC regimen (DOACsame) among patients with nonvalvular atrial fibrillation (NVAF) who developed the first ischemic stroke despite a DOAC from January 1, 2015, to December 31, 2020, in Hong Kong. The primary outcome was recurrent ischemic stroke. Secondary outcomes were intracranial hemorrhage, acute coronary syndrome, and death. We performed competing risk regression analyses to compare the clinical endpoints and determined the predictors of recurrent ischemic stroke in an unweighted multivariable logistic regression model. RESULTS: During the 6-year study period, among 45,946 patients with AF on a DOAC as stroke prophylaxis, 2,908 patients developed ischemic stroke despite a DOAC. A total of 2,337 patients with NVAF were included in the final analyses. Compared with DOACsame, warfarin (aHR 1.96, 95% CI 1.27-3.02, p = 0.002) and DOACswitch (aHR 1.62, 95% CI 1.25-2.11, p < 0.001) were associated with an increased risk of recurrent ischemic stroke. In the DOACsame group, adjunctive antiplatelet agent was not associated with a reduced risk of recurrent ischemic stroke. Diabetes mellitus, concurrent cytochrome P450/P-glycoprotein (CYP/P-gp) modulators, and large artery atherosclerotic disease (LAD) were predictors of recurrent ischemic stroke. DISCUSSION: In patients with NVAF with ischemic stroke despite a DOAC, the increased risk of recurrent ischemic stroke with switching to warfarin called for caution against such practice, while the increased ischemic stroke with DOAC-to-DOAC switch demands further studies. Adjunctive antiplatelet agent did not seem to reduce ischemic stroke relapse. Because diabetes mellitus, the use of CYP/P-gp modulators, and LAD were predictors of recurrent ischemic stroke, further investigations should evaluate whether strict glycemic control, DOAC level monitoring, and routine screening for carotid and intracranial atherosclerosis may reduce ischemic stroke recurrence in these patients. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that in patients with NVAF experiencing an ischemic stroke while being treated with a DOAC, continuing treatment with that DOAC is more effective at preventing recurrent ischemic stroke than switching to a different DOAC or to warfarin.
引用
- Ip YMB, Lau KK, Ko H, et al. Association of Alternative Anticoagulation Strategies and Outcomes in Patients With Ischemic Stroke While Taking a Direct Oral Anticoagulant. Neurology. 2023. PMID: 37225430. doi:10.1212/WNL.0000000000207422
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。